biosimilars

Research Reports

08/15/2022

Kathryn Christensen , MD, MS;

Timothy Dollear , MD, MS;

Eric Gratias , MD, FAAP;

Christopher Linkimer , CPA;

Margaret Rausa , PharmD;

Nick Andrews , PharmD;

Stephen Hamilton , MD;

Dr Hamilton and colleagues outline how eviCore Healthcare offered the option for payer clients to implement a biosimilar preferencing policy, analyzing how this policy affected the rate of biosimilar use and costs.

Dr Hamilton and colleagues...

08/15/2022

Journal of Clinical Pathways

News

First-Line Biosimilar-Based Triplet Effective in HER2-Positive Gastric Cancer

07/08/2020

A first-line triplet regimen consisting of pembrolizumab, biosimilar trastuzumab (Herzuma), and chemotherapy is effective in patients with HER2-positive advanced gastric cancer, according to the results of a phase...

A...

07/08/2020

Journal of Clinical Pathways

News

Cost Savings of Supportive Care Biosimilar in the Medicare OCM Population

06/12/2020

A new study sought to better understand how The Centers for Medicare and Medicaid Services (CMS) reimbursement for pegfilgrastim has been impacted by the introduction of two pegfilgrastim biosimilars into the...

A new...

06/12/2020

Journal of Clinical Pathways

Clinical Pathways GPS

The Place for Biosimilars in Clinical Pathways

12/14/2015

Scott Guerin , PhD;

Richard G. Stefanacci , DO, MGH, MBA, AGSF, CMD;

Payers and at-risk providers are developing clinical pathways with great specificity regarding the preferred drugs that be used. Increasingly, these pathways will include biosimilar products. There are three major...

Payers...

12/14/2015

Journal of Clinical Pathways